ERBB2 and breast carcinoma: The drugs currently used in breast cancer include receptor tyrosine kinase inhibitor lapatinib, HER2 monoclonal antibody trastuzumab, mTOR inhibitor everolimus and the CDK4/6 inhibitor palbociclib (16).